We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 26, 2021

Greater CV Benefits With SGLT2 Inhibitors vs GLP-1 Receptor Agonists Added to Metformin in T2D

Journal of Diabetes and Its Complications

 

Additional Info

Journal of Diabetes and Its Complications
Comparing Cardiovascular Benefits Between GLP-1 Receptor Agonists and SGLT2 Inhibitors as an Add-On to Metformin Among Patients With Type 2 Diabetes: A Retrospective Cohort Study
J Diabetes Complicat 2021 Jun 11;[EPub Ahead of Print], CE DeRemer, SM Vouri, J Guo, WT Donahoo, AG Winterstein, H Shao

Further Reading